Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTZ9SOR)

• DTT Name: Muscarinic acetylcholine receptor M1 (CHRM1) DTT Info
• Gene Name: CHRM1

Molecule-Related Drug & Molecule List

15 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[1]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[2]
Biperiden	DME78OA	Parkinson disease	8A00.0	Approved	[3]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[4]
Cycrimine	DM8C43Q	Parkinson disease	8A00.0	Approved	[5]
Dicyclomine	DMZSDGX	Functional bowel syndrome	DD91.0	Approved	[6]
Diphemanil Methylsulfate	DMXVU6D	Peptic ulcer	DA61	Approved	[7]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[8]
Glycopyrrolate	DM2M3ZA	Anaesthesia	9A78.6	Approved	[9]
Metixene	DM0JE6N	Parkinson disease	8A00.0	Approved	[10]
Oxyphenonium	DMMQHOZ	Visceral spasms	MD81.4	Approved	[11]
Pirenzepine	DMP6M1N	Peptic ulcer	DA61	Approved	[12]
Propantheline	DM2EN6G	Excessive sweating	EE00.Z	Approved	[13]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[14]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[15]

17 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nebracetam	DMFD249	Parkinson disease	8A00.0	Phase 3	[16]
(S)-oxybutynin	DMAV426	Urinary incontinence	MF50.2	Phase 2	[17]
FP-1097	DMC1F2T	Urinary incontinence	MF50.2	Phase 2	[18]
N-DESMETHYLCLOZAPINE	DMVIRN3	Schizoaffective disorder	6A21	Phase 2	[19]
NGX-267	DMJKBAY	Schizophrenia	6A20	Phase 2	[20]
SR-46559A	DMW6UA3	Cognitive impairment	6D71	Phase 2	[8]
Xanomeline tartrate	DMXG5WU	Parkinson disease	8A00.0	Phase 2	[20]
AC-262271	DM36WTQ	Glaucoma/ocular hypertension	9C61	Phase 1	[21]
ANAVEX 2-73	DM67OU4	Alzheimer disease	8A20	Phase 1	[22]
ANAVEX 3-71	DM31634	Frontotemporal dementia	6D83	Phase 1	[23]
Arecoline	DMFJZK3	Parkinson disease	8A00.0	Phase 1	[24]
AZD-6088	DM0WCR4	Neuropathic pain	8E43.0	Phase 1	[25]
B7-2/GM-CSF	DM0LKHV	Dementia	6D80-6D86	Phase 1	[26]
MCD-386	DMFIS4D	Alzheimer disease	8A20	Phase 1	[27]
TAK-071	DMKUT08	Alzheimer disease	8A20	Phase 1	[22]
Thiopilocarpine	DMOLFAU	Cognitive impairment	6D71	Phase 1	[28]
WST-057	DM9PNR6	Peripheral neuropathy	8C0Z	Phase 1	[22]

15 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Telenzepine	DM6PVWS	Chronic obstructive pulmonary disease	CA22	Discontinued in Preregistration	[29]
Darotropium	DMJ4WR6	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[26]
Declopramide	DM5QFT4	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[30]
Rispenzepine	DMVHT6F	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[31]
Talsaclidine fumarate	DM2KH9Y	Alzheimer disease	8A20	Discontinued in Phase 2	[20]
YM-796	DMDXP3C	Cognitive impairment	6D71	Discontinued in Phase 2	[32]
PD-151832	DMO34NQ	Parkinson disease	8A00.0	Discontinued in Phase 1/2	[8]
ITAMELINE	DM8139E	Cognitive impairment	6D71	Discontinued in Phase 1	[8]
Sabcomeline	DMCEOAJ	N. A.	N. A.	Discontinued in Phase 1	[20]
SDZ-210-086	DM8BIV4	Cognitive impairment	6D71	Discontinued in Phase 1	[33]
TAZOMELINE	DM5PZ60	Cognitive impairment	6D71	Discontinued in Phase 1	[8]
AC-260584	DMA93D8	Schizophrenia	6A20	Terminated	[20]
Alvameline	DMLN0Y5	Alzheimer disease	8A20	Terminated	[34]
HIMBACINE	DMGAKD8	N. A.	N. A.	Terminated	[35]
WAY-132983	DM2XTB9	N. A.	N. A.	Terminated	[20]

44 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	DMMNH4K	Discovery agent	N.A.	Investigative	[36]
1,1-diphenyl-2-(3-tropanyl)ethanol	DMZDUSA	Discovery agent	N.A.	Investigative	[37]
1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	DM9KCXI	Discovery agent	N.A.	Investigative	[38]
2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	DMAKZ43	Discovery agent	N.A.	Investigative	[39]
2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione	DM823CD	Discovery agent	N.A.	Investigative	[40]
2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	DM8EV4A	Discovery agent	N.A.	Investigative	[41]
3-(3-benzylamino)-piperidin-2-one	DMYN6Z9	Discovery agent	N.A.	Investigative	[42]
3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	DME81U3	Discovery agent	N.A.	Investigative	[41]
3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	DMIH6JU	Discovery agent	N.A.	Investigative	[43]
3alpha-(bis-chloro-phenylmethoxy)tropane	DMBUZWQ	Discovery agent	N.A.	Investigative	[44]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[20]
6-Dimethylamino-2-methyl-hex-4-ynal oxime	DML2AC1	Discovery agent	N.A.	Investigative	[41]
7-Dimethylamino-3-methyl-hept-5-yn-2-one	DMDY2PQ	Discovery agent	N.A.	Investigative	[41]
7-Dimethylamino-hept-5-yn-2-one	DMH782V	Discovery agent	N.A.	Investigative	[41]
7-Pyrrolidin-1-yl-hept-5-yn-2-one	DMQJ26K	Discovery agent	N.A.	Investigative	[41]
A-987306	DMU34BK	Discovery agent	N.A.	Investigative	[45]
Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DMVEH40	Discovery agent	N.A.	Investigative	[46]
AF150(S)	DMOYADT	Discovery agent	N.A.	Investigative	[47]
AMINOBENZTROPINE	DMT13EW	Discovery agent	N.A.	Investigative	[48]
Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DM6T8YM	Discovery agent	N.A.	Investigative	[49]
Bo(15)PZ	DMCUJH5	Discovery agent	N.A.	Investigative	[50]
BQCA	DMSGIXK	Neurological disorder	6B60	Investigative	[51]
BRL-55473	DMEMZ6Q	Discovery agent	N.A.	Investigative	[52]
CARAMIPEN	DMJFPA9	Discovery agent	N.A.	Investigative	[53]
Cremastrine	DMLJOGK	Discovery agent	N.A.	Investigative	[54]
DAU-5750	DMT14A7	Discovery agent	N.A.	Investigative	[55]
DAU-5884	DMEZVGK	Discovery agent	N.A.	Investigative	[56]
DAU-6202	DMM5SI1	Discovery agent	N.A.	Investigative	[57]
Difluorobenztropine	DM8ABD6	Discovery agent	N.A.	Investigative	[44]
FLUMEZAPINE	DMW0HOG	Discovery agent	N.A.	Investigative	[58]
FM1-10	DM5782Z	Discovery agent	N.A.	Investigative	[59]
FM1-43	DMAP8VY	Discovery agent	N.A.	Investigative	[59]
GNF-PF-5618	DMT8VUS	Discovery agent	N.A.	Investigative	[60]
hexocyclium	DM0HS7L	Discovery agent	N.A.	Investigative	[61]
ISOCLOZAPINE	DM52CPU	Discovery agent	N.A.	Investigative	[62]
ISOLOXAPINE	DMH1BN4	Discovery agent	N.A.	Investigative	[63]
LY-593039	DMQVF41	Discovery agent	N.A.	Investigative	[20]
N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	DMB3E7H	Discovery agent	N.A.	Investigative	[41]
N-methoxyquinuclidine-3-carboximidoyl chloride	DMMB3PG	Discovery agent	N.A.	Investigative	[52]
N-methoxyquinuclidine-3-carboximidoyl fluoride	DMF8IA6	Discovery agent	N.A.	Investigative	[52]
Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DMO325J	Discovery agent	N.A.	Investigative	[49]
R-dimethindene	DM6FVZW	Discovery agent	N.A.	Investigative	[64]
RR(17)PZ	DMP9RLE	Discovery agent	N.A.	Investigative	[50]
SULFOARECOLINE	DM8KYUE	Discovery agent	N.A.	Investigative	[65]

References

• [1] Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
• [2] Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
• [3] Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92.
• [4] Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
• [5] Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
• [6] [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [9] Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
• [10] Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.J Pharmacol Exp Ther.2012 Mar;340(3):595-603.
• [11] Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
• [12] Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
• [13] Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805.
• [14] Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
• [15] The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
• [16] Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist. Jpn J Pharmacol. 1991 Jan;55(1):177-80.
• [17] Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991 Feb;256(2):562-7.
• [18] Clinical pipeline report, company report or official report of FemmePharma.
• [19] N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarin... Neuropsychopharmacology. 2005 Nov;30(11):1986-95.
• [20] Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
• [21] Phase I clinical trial of muscarinic agonist (AC-262271) for treating glaucoma. Acadia Pharmaceuticals.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. Alzheimers Dement. 2018 Jun;14(6):811-823.
• [24] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [25] Evaluation of an Innovative Population Pharmacokinetic-Based Design for Behavioral Pharmacodynamic Endpoints. AAPS J. 2012 December; 14(4): 657-663.
• [26] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [27] The processing of the selective M1 agonist CDD-0102-J by human hepatic drug metabolizing enzymes. Am J Ther. 2005 Jul-Aug;12(4):300-5.
• [28] SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices. Eur J Pharmacol. 1992 Nov 3;222(1):21-5.
• [29] Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. Pulm Pharmacol. 1994 Apr;7(2):91-7.
• [30] Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice. Anticancer Drugs. 1999 Jan;10(1):79-88.
• [31] Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. Am J Respir Crit Care Med. 1995 Sep;152(3):872-8.
• [32] YM796, a novel muscarinic agonist, improves the impairment of learning behavior in a rat model of chronic focal cerebral ischemia. Brain Res. 1995 Jan 9;669(1):107-14.
• [33] Influence of the cholinergic agonist SDZ 210-086 on sleep in healthy subjects. Neuropsychopharmacology. 1993 Nov;9(3):225-32.
• [34] In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
• [35] Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70.
• [36] Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62.
• [37] Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2.
• [38] Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9.
• [39] Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5.
• [40] Design of dual acting anticonvulsant-antimuscarinic succinimide and hydantoin derivatives, Bioorg. Med. Chem. Lett. 7(8):979-984 (1997).
• [41] Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
• [42] Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
• [43] Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90.
• [44] Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
• [45] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [46] 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
• [47] M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. Curr Alzheimer Res. 2007 Dec;4(5):577-80.
• [48] 3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem. 1997 Mar 14;40(6):851-7.
• [49] 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
• [50] On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. J Med Chem. 2005 Dec 1;48(24):7847-59.
• [51] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5436).
• [52] A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
• [53] Muscarinic receptor binding profile of para-substituted caramiphen analogues. J Med Chem. 1991 Oct;34(10):2984-9.
• [54] Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3.
• [55] Synthesis, absolute configuration, conformational analysis and binding affinity properties of enantiomeric forms of DAU 5750, a novel M1-M3 muscari... Bioorg Med Chem. 1994 Dec;2(12):1375-83.
• [56] Doi: 10.1038/bjp.2008.208
• [57] Characterization of muscarinic receptors in guinea-pig uterus. Eur J Pharmacol. 1993 Dec 7;250(2):223-30.
• [58] Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
• [59] Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
• [60] Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
• [61] Hexocyclium derivatives with a high selectivity for smooth muscle muscarinic receptors. Br J Pharmacol. 1990 May;100(1):150-2.
• [62] Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
• [63] Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
• [64] Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10.
• [65] Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6.